Literature DB >> 11338762

Quality of life, health outcomes, and identity for patients with prostate cancer in five different treatment groups.

M E Galbraith1, J M Ramirez, L W Pedro.   

Abstract

PURPOSE/
OBJECTIVES: To describe how different treatments for prostate cancer affect health-related quality of life (QOL), health status, and masculinity.
DESIGN: Longitudinal survey design with descriptive, correlational, and comparative elements.
SETTING: A tertiary medical center and associated clinics in a suburban community in the Southwestern United States. SAMPLE: 185 men with localized prostate cancer were enrolled from five treatment groups: watchful waiting (n = 30), surgery (n = 59), conventional radiation (n = 25), proton-beam radiation (n = 24), and a combination of conventional radiation and proton-beam radiation or mixed-beam radiation (n = 47). At six months, 163 remained on the study; at 12 months, 154 remained: and at 18 months, 153 remained. The average age was 68 years, and 82% of the men were white.
METHODS: Men were enrolled at treatment and given a questionnaire with a self-addressed, stamped envelope for return. Questionnaires were mailed again at 6, 12, and 18 months. MAIN RESEARCH VARIABLES: Health-related QOL health status, prostate treatment-specific symptoms, and sex-role identity.
FINDINGS: No overall difference in health-related QOL or health status was found, but post-hoc analysis revealed specific differences. The differences existed in sexual functioning and gastrointestinal treatment-specific symptoms. No relationship existed between masculinity and health-related QOL.
CONCLUSIONS: Health-related QOL and health status are similar regardless of type of treatment. Radiation tends to produce more gastrointestinal symptoms, and surgery tends to produce more sexual functioning symptoms. Watchful waiting is associated with poorer general health. IMPLICATIONS FOR NURSING PRACTICE: Nurses can provide specific treatment-related information to men who are faced with making treatment decisions for prostate cancer and, in consultation with the healthcare team, can select a treatment best sulted to them.

Entities:  

Mesh:

Year:  2001        PMID: 11338762

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  11 in total

Review 1.  Active surveillance for low-risk prostate cancer: an update.

Authors:  Nathan Lawrentschuk; Laurence Klotz
Journal:  Nat Rev Urol       Date:  2011-04-26       Impact factor: 14.432

2.  Focal therapy for localized prostate cancer -choosing the middle ground.

Authors:  Uri Lindner; John Trachtenberg
Journal:  Can Urol Assoc J       Date:  2009-08       Impact factor: 1.862

3.  Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events.

Authors:  Xiaobo Zhong; Emerson A Lim; Dawn L Hershman; Carol M Moinpour; Joseph Unger; Shing M Lee
Journal:  J Oncol Pract       Date:  2016-02-23       Impact factor: 3.840

4.  Patient and spouse illness beliefs and quality of life in prostate cancer patients.

Authors:  Lisa M Wu; Nihal E Mohamed; Gary Winkel; Michael A Diefenbach
Journal:  Psychol Health       Date:  2012-09-13

5.  Factors influencing patients' acceptance and adherence to active surveillance.

Authors:  David F Penson
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

6.  Active surveillance for favorable-risk prostate cancer: a short review.

Authors:  Nathan Lawrentschuk; Laurence Klotz
Journal:  Korean J Urol       Date:  2010-10-21

7.  Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up.

Authors:  I J Korfage; M-L Essink-Bot; A C J W Janssens; F H Schröder; H J de Koning
Journal:  Br J Cancer       Date:  2006-04-24       Impact factor: 7.640

8.  Different therapeutic approaches on quality of life in patients with inflammatory bowel disease.

Authors:  Junjie Xu; Hui Lin; Xu Feng; Minyue Tang; Jun Shen; Zhihua Ran
Journal:  BMC Gastroenterol       Date:  2014-11-25       Impact factor: 3.067

Review 9.  Quality of life after treatment for prostate cancer.

Authors:  David F Penson; Mark S Litwin
Journal:  Curr Urol Rep       Date:  2003-06       Impact factor: 2.862

Review 10.  Focal therapy for prostate cancer: rationale and treatment opportunities.

Authors:  V Kasivisvanathan; M Emberton; H U Ahmed
Journal:  Clin Oncol (R Coll Radiol)       Date:  2013-06-04       Impact factor: 4.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.